Literature DB >> 33622931

Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors.

Innocenza Palaia1, Federica Tomao2, Anna DI Pinto3, Angelina Pernazza4, Giusi Santangelo1, Nicoletta D'Alessandris4, Lucia Manganaro4, Antonio Arno1, Violante DI Donato1, Giorgia Perniola1, Carlo Della Rocca4, Pierluigi Benedetti Panici1.   

Abstract

BACKGROUND/AIM: Treatment of locally advanced cervical cancer (LACC) consists of concomitant chemoradiation or neoadjuvant chemotherapy (NACT) plus radical surgery (RS). This study analyzed the prognostic role of neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), tumor infiltrating lymphocytes (TILs), and PD-L1 expression in LACC patients, treated with NACT+RS. PATIENTS AND METHODS: We prospectively analyzed 37 LACC patients treated from December 2016 to September 2019. Patients were submitted to pelvic examination, biopsy and imaging.
RESULTS: In 65% of cases, a nodal involvement was present at pre-treatment MRI. All cancers showed the presence of stromal TILs and PD-L1 staining of inflammatory cells. No significant correlations were found between clinicopathological parameters and the number of TILs and PDL-1 at baseline. After NACT, 29 patients (78%) were submitted to RS; 28% of patients showed pathological complete response, 62% partial response and 10% stable disease. Seven (24%) patients reported a positive node. Patients with high levels of stromal TILs and low NLR and PLR showed a significantly better response to NACT. No significant correlation was observed between PD-L1 expression and response to NACT.
CONCLUSION: The number of TILs, the expression of PDL1, and NLR and PLR ratios correlate significantly with the response of LACC patients to NACT. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Locally advanced cervical cancer; PD-L1; TILs; neoadjuvant chemotherapy

Year:  2021        PMID: 33622931      PMCID: PMC8045068          DOI: 10.21873/invivo.12379

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  40 in total

1.  Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer.

Authors:  P Widschwendter; W Janni; C Scholz; A De Gregorio; N De Gregorio; T W P Friedl
Journal:  Arch Gynecol Obstet       Date:  2019-11-06       Impact factor: 2.344

2.  Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Authors:  Stefan Diem; Sabine Schmid; Mirjam Krapf; Lukas Flatz; Diana Born; Wolfram Jochum; Arnoud J Templeton; Martin Früh
Journal:  Lung Cancer       Date:  2017-07-24       Impact factor: 5.705

Review 3.  Cervical cancer.

Authors:  Paul A Cohen; Anjua Jhingran; Ana Oaknin; Lynette Denny
Journal:  Lancet       Date:  2019-01-12       Impact factor: 79.321

4.  Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.

Authors:  Emeka K Enwere; Elizabeth N Kornaga; Michelle Dean; Theodora A Koulis; Tien Phan; Maria Kalantarian; Martin Köbel; Prafull Ghatage; Anthony M Magliocco; Susan P Lees-Miller; Corinne M Doll
Journal:  Mod Pathol       Date:  2017-01-06       Impact factor: 7.842

5.  Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.

Authors:  Rezaul Karim; Ekaterina S Jordanova; Sytse J Piersma; Gemma G Kenter; Lieping Chen; Judith M Boer; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

6.  Effect of smoking on high-grade cervical cancer in women on the basis of human papillomavirus infection studies.

Authors:  Jian-Hong Fang; Xue-Mei Yu; Shu-Hong Zhang; Yan Yang
Journal:  J Cancer Res Ther       Date:  2018       Impact factor: 1.805

7.  Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Authors:  Silvia Darb-Esfahani; Catarina Alisa Kunze; Hagen Kulbe; Jalid Sehouli; Stephan Wienert; Judith Lindner; Jan Budczies; Michael Bockmayr; Manfred Dietel; Carsten Denkert; Ioana Braicu; Korinna Jöhrens
Journal:  Oncotarget       Date:  2016-01-12

8.  Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer.

Authors:  Rui Chen; Yi Gong; Dongling Zou; Lifeng Wang; Li Yuan; Qi Zhou
Journal:  PeerJ       Date:  2019-10-11       Impact factor: 2.984

Review 9.  Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis.

Authors:  X Yu; Z Zhang; Z Wang; P Wu; F Qiu; J Huang
Journal:  Clin Transl Oncol       Date:  2015-10-12       Impact factor: 3.405

10.  Expression and clinical significance of programmed death-1 on lymphocytes and programmed death ligand-1 on monocytes in the peripheral blood of patients with cervical cancer.

Authors:  Ying Zhang; Weipei Zhu; Xueguang Zhang; Qiuxia Qu; Liyuan Zhang
Journal:  Oncol Lett       Date:  2017-09-29       Impact factor: 2.967

View more
  3 in total

Review 1.  A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment.

Authors:  Iske F van Luijk; Sharissa M Smith; Maria C Marte Ojeda; Arlene L Oei; Gemma G Kenter; Ekaterina S Jordanova
Journal:  J Clin Med       Date:  2022-04-19       Impact factor: 4.964

2.  Intravoxel Incoherent Motion (IVIM) MR Quantification in Locally Advanced Cervical Cancer (LACC): Preliminary Study on Assessment of Tumor Aggressiveness and Response to Neoadjuvant Chemotherapy.

Authors:  Miriam Dolciami; Silvia Capuani; Veronica Celli; Alessandra Maiuro; Angelina Pernazza; Innocenza Palaia; Violante Di Donato; Giusi Santangelo; Stefania Maria Rita Rizzo; Paolo Ricci; Carlo Della Rocca; Carlo Catalano; Lucia Manganaro
Journal:  J Pers Med       Date:  2022-04-15

3.  Assessing Post-Treatment Pathologic Tumor Response in Female Genital Tract Carcinomas: An Update.

Authors:  Frediano Inzani; Damiano Arciuolo; Giuseppe Angelico; Angela Santoro; Antonio Travaglino; Nicoletta D'Alessandris; Giulia Scaglione; Michele Valente; Federica Cianfrini; Antonio Raffone; Gian Franco Zannoni
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.